Autolus Therapeutics plc Share-based Payment Arrangement, Noncash Expense
Autolus Therapeutics plc (AUTL) reported Share-based Payment Arrangement, Noncash Expense of $23.81 million for the 9-month period ending 2019-09-30, per its 6-K filed 2019-11-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2019-11-07
- Autolus Therapeutics plc share-based payment arrangement, noncash expense for the quarter ending 2019-09-30 was $7.58M, a 245.76% increase year-over-year.
- Autolus Therapeutics plc share-based payment arrangement, noncash expense for the quarter ending 2018-09-30 was $2.19M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month |
|---|---|---|---|
| 2019-09-30 | $7.58M derived: 6-K 9 month − 6-K 6 month · filed 2019-11-07 | $23.81M 6-K · filed 2019-11-07 | |
| 2019-06-30 | $16.23M 6-K · filed 2019-08-08 | ||
| 2018-09-30 | $2.19M derived: 6-K 9 month − 6-K 6 month · filed 2019-11-07 | $5.91M 6-K · filed 2019-11-07 | |
| 2018-06-30 | $3.71M 6-K · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |